Archive · 28 Jul 2025
Celcuity Drug Combo Shows Promise in Breast Cancer Trial
Scientists are testing a new treatment for a type of advanced breast cancer.
This new treatment combines three drugs: gedatolisib, Ibrance, and Faslodex.
In a study, this combination was very effective in slowing down the cancer's growth compared to using only one drug, Faslodex.
Patients on the combination lived longer without their cancer getting worse.
The new treatment also seemed to cause fewer side effects than in earlier studies.
Celcuity, the company that developed gedatolisib, is planning to ask for permission to sell this treatment in the U.S.
Celcuity's experimental drug combination delayed the progression of advanced breast cancer.
The combination of gedatolisib, Ibrance, and Faslodex reduced the risk of disease progression by 76%.
Patients on the combination treatment lived for 9.3 months without progression.
A double combination of gedatolisib and Ibrance reduced the risk of disease progression by 67%.
Celcuity plans to apply for U.S. marketing approval in the fourth quarter.
- Who
- Celcuity conducted the study, testing a combination treatment including its drug gedatolisib.
- What
- A combination drug treatment for advanced breast cancer showed positive results in a study.
- When
- The study was recently conducted, and Celcuity expects to apply for U.S. marketing approval in the fourth quarter.
- Where
- The location of the study is not specified.
- Why
- To evaluate the effectiveness of the drug combination in treating advanced breast cancer.
- Drug Combination
- gedatolisib + Ibrance + Faslodex
- Cancer Type
- HR /HER2- advanced breast cancer
- Risk Reduction
- 76% for the triple combination
- Progression-Free Survival (Triple Combo)
- 9.3 months
- Risk Reduction (Double Combo)
- 67% (gedatolisib + Ibrance)
- Company
- Celcuity